Elevation Oncology, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 95.08 million compared to USD 32.04 million a year ago. Basic loss per share from continuing operations was USD 4.09 compared to USD 2.64 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.805 USD | -0.91% | +2.14% | +609.50% |
14/05 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
02/05 | Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+609.50% | 21Cr | |
+10.00% | 12TCr | |
+10.33% | 11TCr | |
-11.20% | 2.34TCr | |
-1.69% | 2.21TCr | |
-10.23% | 1.83TCr | |
-41.92% | 1.66TCr | |
-15.46% | 1.6TCr | |
+6.88% | 1.4TCr | |
+17.77% | 1.17TCr |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022